Articles written by Vandana Singh - Benzinga

Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds

|Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing alcohol use, though high costs may limit broad access.

Eli Lilly Collaborates With Rznomics On Hearing Loss Treatment In $1.3 Billion Pact

|Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.

Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda

|Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

|Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels.

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

|Nkarta posts a smaller Q1 loss than expected and maintains strong cash reserves while analysts debate its trial strategy and market position.

CPI Undershoots But Core Inflation Stays Stubborn: JP Morgan

|U.S. inflation rose 2.3% annually in April, with shelter costs up and key goods like used cars and apparel posting monthly price declines.

Why Is Biohaven Stock Falling On Thursday?

|Biohaven secures $250 million from Oberland Capital, with total cash reaching $518 million to support troriluzole launch and operations.

Why Is UnitedHealth Stock Trading Lower On Thursday?

|UnitedHealth faces DOJ scrutiny and analyst downgrades after reports of a criminal Medicare fraud probe and executive leadership shakeups.

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030

|Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up

|CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.

FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases

|FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront.

FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors

|Merck's Welireg wins FDA approval for rare PPGL tumors; Q1 2025 sales reach $137M, marking a 62% year-over-year increase.

Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds

|Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing alcohol use, though high costs may limit broad access.

Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat

|Exelixis lifts 2025 revenue outlook after strong Q1 driven by Cabometyx sales surge and early traction in the neuroendocrine tumor market.

Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity

|Bluebird Bio revised its agreement with Carlyle and SK Capital, adding a $5 per share cash option for stockholders ahead of deal completion.

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

|Exelixis beats Q1 estimates with strong Cabometyx sales, raises 2025 guidance, and begins Phase 1 trial of its novel NK cell engager, XB628.

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

|Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and cardiometabolic diseases.

GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion

|GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models

|Channel Therapeutics reports CT2000 reduced eye pain in preclinical trials, with plans to enter human testing for acute and chronic indications.

CPI Undershoots But Core Inflation Stays Stubborn: JP Morgan

|U.S. inflation rose 2.3% annually in April, with shelter costs up and key goods like used cars and apparel posting monthly price declines.